![Cosmas Giallourakis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Cosmas Giallourakis
Presidente en Stylus Medicine, Inc. .
Cargos activos de Cosmas Giallourakis
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
RA Capital Management LP (Private Equity)
![]() RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Inversor de Capital Privado | 01/11/2021 | - |
Stylus Medicine, Inc.
![]() Stylus Medicine, Inc. Medical SpecialtiesHealth Technology Stylus Medicine, Inc. is a company focused on developing innovative solutions to combat diseases using cutting-edge genome engineering and chromatin regulation technologies. Stylus Medicine is based in Boston, MA. The company is backed by RA Ventures and Khosla Ventures. | Presidente | - | - |
Historial de carrera de Cosmas Giallourakis
Antiguos cargos conocidos de Cosmas Giallourakis.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Director/Miembro de la Junta | 01/06/2016 | 31/08/2019 |
Design Pharmaceuticals, Inc.
![]() Design Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Design Pharmaceuticals, Inc. harnesses nature's chemistry to develop breakthrough therapeutics. The company is based in Cambridge, MA. The company uses engineering-inspired biotechnologies to redesign the process of small molecule-based drug discovery and development, saving time and costs. The company's platform is based on ultrahigh-throughput technologies that biomine and test drug-like molecules from nature at unprecedented speed and scale on hundreds of GPCR targets simultaneously. Design Pharmaceuticals' cell-free biosynthesis eliminates the inherent limitations of traditional chemistry or using platforms based on live production strains, further accelerating lead compound optimization. The company's business model aims to build a continuously growing portfolio of joint development and license agreements with pharma partners. The company was founded by Dirk Löffert, Cosmas Giallourakis, Marnix Medema, Rob Nicol, Noah W. Palm, Michael Jewett, Andrew Griffiths. Dirk Löffert has been the CEO since incorporation. | Fundador | 01/10/2019 | - |
Formación de Cosmas Giallourakis.
Massachusetts Institute of Technology | Undergraduate Degree |
New Jersey Medical School | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 5 |
Japón | 2 |
2 |
Operativa
Private Equity Investor | 1 |
Founder | 1 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 3 |
Finance | 3 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
Empresas privadas | 3 |
---|---|
RA Capital Management LP (Private Equity)
![]() RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Design Pharmaceuticals, Inc.
![]() Design Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Design Pharmaceuticals, Inc. harnesses nature's chemistry to develop breakthrough therapeutics. The company is based in Cambridge, MA. The company uses engineering-inspired biotechnologies to redesign the process of small molecule-based drug discovery and development, saving time and costs. The company's platform is based on ultrahigh-throughput technologies that biomine and test drug-like molecules from nature at unprecedented speed and scale on hundreds of GPCR targets simultaneously. Design Pharmaceuticals' cell-free biosynthesis eliminates the inherent limitations of traditional chemistry or using platforms based on live production strains, further accelerating lead compound optimization. The company's business model aims to build a continuously growing portfolio of joint development and license agreements with pharma partners. The company was founded by Dirk Löffert, Cosmas Giallourakis, Marnix Medema, Rob Nicol, Noah W. Palm, Michael Jewett, Andrew Griffiths. Dirk Löffert has been the CEO since incorporation. | Commercial Services |
Stylus Medicine, Inc.
![]() Stylus Medicine, Inc. Medical SpecialtiesHealth Technology Stylus Medicine, Inc. is a company focused on developing innovative solutions to combat diseases using cutting-edge genome engineering and chromatin regulation technologies. Stylus Medicine is based in Boston, MA. The company is backed by RA Ventures and Khosla Ventures. | Health Technology |
- Bolsa de valores
- Insiders
- Cosmas Giallourakis
- Experiencia